Amgen Inc. $AMGN Holdings Trimmed by Oak Associates Ltd. OH

Oak Associates Ltd. OH reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 11.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 110,466 shares of the medical research company’s stock after selling 14,795 shares during the quarter. Amgen accounts for 2.6% of Oak Associates Ltd. OH’s investment portfolio, making the stock its 12th biggest holding. Oak Associates Ltd. OH’s holdings in Amgen were worth $38,867,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of AMGN. Inceptionr LLC boosted its position in shares of Amgen by 75.5% in the first quarter. Inceptionr LLC now owns 5,432 shares of the medical research company’s stock worth $1,911,000 after buying an additional 2,337 shares during the period. Dickmeyer Boyce Financial Management Inc. purchased a new position in shares of Amgen during the first quarter valued at $1,016,000. Sei Investments Co. raised its position in Amgen by 1.5% during the first quarter. Sei Investments Co. now owns 356,625 shares of the medical research company’s stock valued at $125,474,000 after buying an additional 5,320 shares during the period. Cetera Investment Advisers lifted its stake in Amgen by 0.8% in the 1st quarter. Cetera Investment Advisers now owns 345,260 shares of the medical research company’s stock worth $121,480,000 after acquiring an additional 2,800 shares in the last quarter. Finally, Wealthspire Retirement LLC lifted its stake in Amgen by 1.8% in the 1st quarter. Wealthspire Retirement LLC now owns 5,737 shares of the medical research company’s stock worth $2,019,000 after acquiring an additional 101 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.85% of the company’s stock.

Amgen Trading Up 1.5%

Amgen stock opened at $371.50 on Friday. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The company has a market capitalization of $200.50 billion, a price-to-earnings ratio of 25.85, a PEG ratio of 3.70 and a beta of 0.41. Amgen Inc. has a one year low of $269.77 and a one year high of $391.29. The company’s fifty day moving average price is $350.28 and its two-hundred day moving average price is $351.63.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. During the same period last year, the company earned $4.90 earnings per share. The business’s revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, analysts forecast that Amgen Inc. will post 22.31 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on AMGN. BMO Capital Markets reaffirmed an “outperform” rating and set a $400.00 target price on shares of Amgen in a research note on Wednesday, July 1st. Argus reduced their price target on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research report on Wednesday, May 20th. Morgan Stanley decreased their price target on shares of Amgen from $340.00 to $333.00 and set an “equal weight” rating for the company in a report on Wednesday, July 8th. Piper Sandler reaffirmed an “overweight” rating on shares of Amgen in a research report on Friday, June 12th. Finally, Weiss Ratings lowered shares of Amgen from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, July 15th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $356.62.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.